Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2020

View Archived Issues

FDA clears IND application for first-in-human trial of IO-202

FDA approves Tauvid for PET imaging in patients being evaluated for AD

Phenotype detection platform screens for new PD drugs

Tumor types have distinct microbiomes

New alcohol risk genes in Caucasians

A series of benzimidazolones causing rapid degradation of BCL6 as potential therapeutics for DLBCL

New inhibitors of the minichromosomal maintenance protein with potential for the treatment of NSCLC

LMP2 inhibition shows therapeutic potential in AD by protecting against neuroinflammation

Edgewise Therapeutics presents new myosin inhibitors

New JAK-2 inhibitors identified at the Dana-Farber Cancer Institute

Rudong Ringene Pharmaceuticals patents PTPN11 inhibitors

New histone deacetylase inhibitors discovered at Merck & Co.

Genentech and Roche synthesize new RAS protein inhibitors

Novus reports topline phase IIa data on OP-0201 in acute otitis media

Gilead reports phase III data on remdesivir in moderate COVID-19 pneumonia

FDA clears Opko to begin phase II trial of Rayaldee for mild to moderate COVID-19

Ocugen discontinues phase III trial of OCU-300 for ocular graft-versus-host disease

Interim phase Ib data with ALRN-6924 show chemoprotective effect

Avelumab does not show activity in recurrent osteosarcoma trial

FDA approves Brilinta to reduce first heart attack in patients with coronary artery disease

Mesothelin-targeting CAR MCY-M11 appears to be safe in phase I trial

Nicox's NCX-470 enters phase III development

CTI enrolling patients in phase III PREVENT trial of pacritinib in severe COVID-19

Olokizumab obtains first approval in Russia

Phase III study of sulopenem in cUTI does not meet primary endpoint

FDA approves Taltz for active nonradiographic axial spondyloarthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...